Vericel Corp. (VCEL)
42.36
-0.32
(-0.76%)
USD |
NASDAQ |
Aug 24, 16:00
42.36
0.00 (0.00%)
After-Hours: 20:00
Vericel Enterprise Value : 2.116B for Aug. 21, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 2.116B |
| August 20, 2026 | 2.087B |
| August 19, 2026 | 2.162B |
| August 18, 2026 | 2.197B |
| August 17, 2026 | 2.163B |
| August 14, 2026 | 2.194B |
| August 13, 2026 | 2.211B |
| August 12, 2026 | 2.221B |
| August 11, 2026 | 2.202B |
| August 10, 2026 | 2.181B |
| August 07, 2026 | 2.239B |
| August 06, 2026 | 2.222B |
| August 05, 2026 | 2.253B |
| August 04, 2026 | 2.303B |
| August 03, 2026 | 2.289B |
| July 31, 2026 | 2.284B |
| July 30, 2026 | 2.368B |
| July 29, 2026 | 2.318B |
| July 28, 2026 | 2.322B |
| July 27, 2026 | 2.251B |
| July 24, 2026 | 2.237B |
| July 23, 2026 | 2.237B |
| July 22, 2026 | 2.212B |
| July 21, 2026 | 2.293B |
| July 20, 2026 | 2.280B |
| Date | Value |
|---|---|
| July 17, 2026 | 2.319B |
| July 16, 2026 | 2.379B |
| July 15, 2026 | 2.323B |
| July 14, 2026 | 2.291B |
| July 13, 2026 | 2.362B |
| July 10, 2026 | 2.337B |
| July 09, 2026 | 2.404B |
| July 08, 2026 | 2.338B |
| July 07, 2026 | 2.335B |
| July 06, 2026 | 2.315B |
| July 02, 2026 | 2.336B |
| July 01, 2026 | 2.242B |
| June 30, 2026 | 2.209B |
| June 29, 2026 | 2.250B |
| June 26, 2026 | 2.309B |
| June 25, 2026 | 2.139B |
| June 24, 2026 | 2.078B |
| June 23, 2026 | 2.011B |
| June 22, 2026 | 2.015B |
| June 18, 2026 | 1.997B |
| June 17, 2026 | 1.947B |
| June 16, 2026 | 1.913B |
| June 15, 2026 | 1.904B |
| June 12, 2026 | 1.862B |
| June 11, 2026 | 1.919B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Krystal Biotech, Inc. | 9.421B |
| AbbVie, Inc. | 532.50B |
| Marker Therapeutics, Inc. | 11.25M |
| TG Therapeutics, Inc. | 8.510B |
| ADMA Biologics, Inc. | 2.285B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 2.206M |
| Revenue (Quarterly) | 77.46M |
| Total Expenses (Quarterly) | 75.25M |
| EPS Diluted (Quarterly) | 0.0422 |
| Gross Profit Margin (Quarterly) | 72.82% |
| Profit Margin (Quarterly) | 2.85% |
| Earnings Yield | 1.09% |
| Operating Earnings Yield | 0.83% |
| Normalized Earnings Yield | 1.091 |